InsiderClue
← All stocks

Olema Pharmaceuticals, Inc.

OLMA Net buying
CIK 0001750284 #2588 in the set updated 20 Sep 2026
Bought (120 mo)
$88.75M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$95.43M
$3.55M on a plan · $22.47M straight out of an exercise
Sold at will
$69.42M
65 of 127 sales
Net
−$6.69M
+$19.33M against sales at will

By person

19 insiders · 162 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
BVF PARTNERS L P/IL entity
Director
$44.14M (11)
—
+$44.14M
547,082
0.6253%
$6.41M
—
Paradigm Biocapital Advisors LP entity
10% owner
$1.16M (1)
$35.80M (2)
−$34.64M
783,118
0.8950%
$9.17M
−74.6%
Graham G. Walmsley
Director
$33.64M (6)
$22.18M (3)
+$11.46M
2,568,875
2.94%
$30.09M
+237.3%
Cormorant Asset Management, LP entity
Former 10% Owner
$8.08M (1)
—
+$8.08M
3,270,544
3.74%
$38.31M
—
Zojwalla Naseem
CHIEF MEDICAL OFFICER
—
$7.99M (10) scheduled
−$7.99M
4,488
0.0051%
$52.57K
−80.7%
CLARK IAN T
Director
—
$7.87M (3) scheduled
−$7.87M
0
0.0000%
$0.00
—
Harmon Cyrus
Director
—
$6.37M (50)
−$6.37M
941,826
1.08%
$11.03M
−8.2%
Myles David C.
CH. DISCOV. & NON-CLIN DEV OFF
—
$5.61M (20) scheduled
−$5.61M
842,453
0.9628%
$9.87M
+38.8%
Kovacs Shane William Charles
CH. OPERATING & FINANCIAL OFF.
— (2)
$3.57M (8)
−$3.57M
139,727
0.1597%
$1.64M
+644.4%
Horn Kinney
Chief Business Officer
—
$2.98M (16) scheduled
−$2.98M
2,458
0.0028%
$28.79K
0.0%
Bohen Sean
PRESIDENT AND CEO
—
$2.11M (12)
−$2.11M
237,650
0.2716%
$2.78M
+806.1%
Bain Capital Life Sciences Investors, LLC entity
10% owner
$1.73M (1)
—
+$1.73M
4,300,000
4.91%
$50.37M
−42.7%
Mitchell Shawnte
CHIEF LEGAL OFFICER
—
$951.50K (3) scheduled
−$951.50K
0
0.0000%
$0.00
—
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
10% owner
—
—
—
1,725,406
1.97%
$20.21M
—
Kushner Peter J.
CHIEF SCIENTIFIC OFFICER
—
—
—
1,431,672
1.64%
$16.77M
+54.1%
RAPPAPORT ANDREW
Director
—
—
—
866,979
0.9909%
$10.16M
+68.8%
MCCORMICK FRANK
Director
—
—
—
275,373
0.3147%
$3.23M
+390.4%
BUTITTA CYNTHIA M
Director
—
—
—
83,876
0.0959%
$982.52K
—
Austin Sasha Lu
VP of Finance and Controller
—
—
—
16,188
0.0185%
$189.63K
+260.7%

Individual transactions

22
Insider
Date
Role
Action
Shares
Price
Amount
Bain Capital Life Sciences Investors, LLC
8 Jan 2025
10% owner
Buy indirect
300,000
$5.76
$1.73M
Graham G. Walmsley
17 Dec 2024
Director
Buy indirect
700,761
$6.75
$4.73M
Paradigm Biocapital Advisors LP
6 Dec 2023
10% owner
Buy indirect
100,000
$11.60
$1.16M
Graham G. Walmsley
5 Dec 2023
Director
Buy indirect
50,000
$13.09
$654.25K
Graham G. Walmsley
5 Dec 2023
Director
Buy indirect
50,000
$14.95
$747.48K
Graham G. Walmsley
5 Dec 2023
Director
Buy indirect
31,870
$14.73
$469.55K
BVF PARTNERS L P/IL
12 Sep 2023
Director
Buy
52,801
$9.84
$519.56K
BVF PARTNERS L P/IL
12 Sep 2023
Director
Buy
677,853
$9.84
$6.67M
BVF PARTNERS L P/IL
12 Sep 2023
Director
Buy
775,278
$9.84
$7.63M
Graham G. Walmsley
12 Sep 2023
Director
Buy indirect
508,130
$9.84
$5.00M
Kovacs Shane William Charles
6 Apr 2023
CH. OPERATING & FINANCIAL OFF.
Buy
10,000
—
no price
Kovacs Shane William Charles
2 Sep 2022
CH. OPERATING & FINANCIAL OFF.
Buy
20,000
—
no price
BVF PARTNERS L P/IL
10 Jun 2022
Director
Buy
41,417
$4.03
$167.10K
BVF PARTNERS L P/IL
10 Jun 2022
Director
Buy
158,583
$4.03
$639.80K
BVF PARTNERS L P/IL
30 Nov 2021
Director
Buy
35,268
$9.39
$331.18K
BVF PARTNERS L P/IL
30 Nov 2021
Director
Buy
341,977
$9.39
$3.21M
BVF PARTNERS L P/IL
30 Nov 2021
Director
Buy
362,430
$9.39
$3.40M
Graham G. Walmsley
23 Nov 2020
Director
Buy indirect
1,160,000
$19.00
$22.04M
Cormorant Asset Management, LP
23 Nov 2020
Former 10% Owner
Buy indirect
425,000
$19.00
$8.08M
BVF PARTNERS L P/IL
19 Nov 2020
Director
Buy
74,991
$19.00
$1.42M
BVF PARTNERS L P/IL
19 Nov 2020
Director
Buy
446,425
$19.00
$8.48M
BVF PARTNERS L P/IL
19 Nov 2020
Director
Buy
613,918
$19.00
$11.66M
Show all 162 transactions →

What was left out

Form 4 filings counted 203
Amendments (4/A) skipped 14
Filings about a different issuer 0
Unreadable filings 0
Joint filings 15
Sales on a Rule 10b5-1 plan 26
Sales straight out of an exercise 36
Sales at will 65
Transactions with no price 2
Shares from compensation/vesting 24,931,528
Sales filed before the plan box existed 11
History held since 19 Nov 2020